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background: To assess the association between biomarkers and outcomes in patients with a heart failure (HF) related hospitalization.
Methods: We conducted a retrospective database analysis utilizing the Cerner Health Facts® database. Index hospitalization was defined as the 
first HF (primary or secondary ICD-9 code) hospitalization between Jan 2008 and March 2012. Patient demographics, vital signs, comorbidities, and 
HF medication use were collected. The main outcomes of interest were costs during the index hospitalization, cumulative length of stay (LOS), as well 
as 30, 60, and 180 day mortality and readmissions. We assessed multiple biomarkers including: cardiac (troponin, NT-proBNP, BNP), inflammatory 
(hs-CRP), renal (SCr, BUN), and liver (AST, ALT, total bilirubin). The estimated Glomerular Filtration Rate (eGFR) was also assessed. Statistical models 
were built for each outcome of interest (mortality - full and reduced logistic models, re-admissions - negative binomial regression, and LOS/costs - 
general linear models assuming a gamma distribution).
results: A total of 104,795 patients with a mean age of 71.6 years and 52.7% female were included. The most common comorbidities were 
hypertension (64.1%) and coronary artery disease (49.9%). The mean LOS of the index hospitalization was 7.1 days and the mortality rate was 
5.7%. Select biomarkers BUN, SCr eGFR, AST, bilirubin, and troponin were consistently significant predictors of mortality risk and cumulative LOS in 
both the unadjusted and adjusted analyses (p<0.0001) for all time points. Renal biomarkers (BUN, SCr) and eGFR were also consistently significant 
(p<0.0001) for re-admission risk for all time points. In unadjusted and adjusted cost models, eGFR, troponin, AST, and ALT were significant for all 
time points (p<0.0001).
conclusion: Renal function measures are associated with clinical and cost outcomes in patients hospitalized with HF. Other biomarkers were 
associated but were not as consistent across time points or outcomes for HF. Increased vigilance of renal biomarkers may be warranted to better 
assess risk and promote proactive management to improve outcomes in this population.
